Paper · 28315433
Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway.
Xu X and 8 others. Cancer Lett, 2017. Cited by 44 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. Papers, record 28315433. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28315433
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway.
- PubMed
Topics27
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Pancreatic Ductal | Major topic |
| Cell Movement | Major topic |
| Cell Proliferation | Major topic |
| MAP Kinase Signaling System | Major topic |
| Mitogen-Activated Protein Kinase 1 | Major topic |
| Mitogen-Activated Protein Kinase 3 | Major topic |
| Pancreatic Neoplasms | Major topic |
| Semaphorins | Major topic |
| Animals | |
| Apoptosis | |
| Cell Line, Tumor | |
| Enzyme Activation | |
| Epithelial-Mesenchymal Transition | |
| Female | |
| Humans | |
| Male | |
| Mice, Inbred NOD | |
| Mice, SCID | |
| Middle Aged | |
| Neoplasm Grading | |
| Neoplasm Invasiveness | |
| Neoplasm Staging | |
| RNA Interference | |
| Signal Transduction | |
| Time Factors | |
| Transfection | |
| Tumor Burden |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 44 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,169,874 | Single-nucleus RNA sequencing reveals the effects of key regulators on human pancreatic adenocarcinoma and its tumor microenvironment. | J Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/42169874 | PubMed |
| 41,792,569 | Construction of a SEMA3 family-based model to predict prognosis and molecular subtypes in pancreatic ductal adenocarcinoma. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41792569 | PubMed |
| 41,712,286 | Sympathetic nerve-fibroblast crosstalk drives nerve injury, fibroblast activation, and matrix remodeling in pancreatic cancer. | JCI Insight | 2026 | https://conductscience.org/library/papers/41712286 | PubMed |
| 40,402,249 | Cancer-associated fibroblast-derived SEMA3C facilitates colorectal cancer liver metastasis via NRP2-mediated MAPK activation. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40402249 | PubMed |
| 39,506,070 | Construction and validation of a prognostic signature based on microvascular invasion and immune-related genes in hepatocellular carcinoma. | Sci Rep | 2024 | https://conductscience.org/library/papers/39506070 | PubMed |
| 39,413,197 | Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming. | Sci Adv | 2024 | https://conductscience.org/library/papers/39413197 | PubMed |
| 38,528,115 | Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer. | Sci Rep | 2024 | https://conductscience.org/library/papers/38528115 | PubMed |
| 38,495,381 | Genetic alterations in the neuronal development genes are associated with changes of the tumor immune microenvironment in pancreatic cancer. | Ann Pancreat Cancer | 2023 | https://conductscience.org/library/papers/38495381 | PubMed |
| 38,321,460 | Integrated bioinformatics analysis of SEMA3C in tongue squamous cell carcinoma using machine-learning strategies. | Cancer Cell Int | 2024 | https://conductscience.org/library/papers/38321460 | PubMed |
| 38,006,346 | Modulation of semaphorin 3C & 4D expression in cancerous tissues from individuals with laryngeal squamous cell carcinoma. | Indian J Med Res | 2023 | https://conductscience.org/library/papers/38006346 | PubMed |
1 to 10 of 33
See all 33 cited byGenes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MAPK1 | 5,594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| MAPK3 | 5,595 | PubTator's text mining | https://conductscience.org/library/genes/5595 | NCBI Gene |
| SEMA3C | 10,512 | PubTator's text mining | https://conductscience.org/library/genes/10512 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28315433
GET https://conductscience.org/api/papers/v1/28315433/cited_by?page=2